Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTA1 | P08263 | 3/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | CD14 | P08571 | 2/20 | 0.34 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626907 | 1.00 | GSTA1 (0.43) | GSTA1GSTP1SMN1; SMN2LMNACRHBP | |
| SCHEMBL2626909 | 1.00 | GSTA1 (0.43) | GSTA1GSTP1SMN1; SMN2LMNACRHBP | |
| SCHEMBL2626906 | 0.89 | SMN1; SMN2 (0.37) | GSTA1GSTP1SMN1; SMN2LMNACRHBP | |
| SCHEMBL20121194 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL20121197 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL2626905 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL2626911 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL2626908 | 0.81 | SMN1; SMN2 (0.36) | GSTA1GSTP1SMN1; SMN2LMNACRHBP | |
| SCHEMBL18505803 | 0.81 | CD69 (0.36) | GSTA1GSTP1SMN1; SMN2LMNACRHBP | |
| SCHEMBL18505802 | 0.80 | CD69 (0.36) | GSTA1GSTP1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8270554-B2 | Methods of producing cesium-131 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8158088-B2 | Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100296616-A1 | METHODS OF PRODUCING CESIUM-131 | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | UT-BATTELLE, LLC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | CANX, CBX6, CALD1 | GSTA1 3145/4885GSTP1 4078/4885SMN1; SMN2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.